Abstract
Background:
Diabetes mellitus (DM) is the highest prevalent endocrine illness that exhibits hyperglycemia, hyperlipidemia and protein metabolism disorders also elevated risk of several complications, including vascular disorders. A variety of polypeptide agents can be found in bee venom. The two main ingredients of bee venom are phospholipase A2 and mellitin. These constituents enhance the release of insulin from the Beta islands of pancreas. The purpose of the current work was to demonstrate the hypoglycemic and hypolipidemic effects of bee venom on male diabetic rats that induced by alloxan.
Methods:
The experimental investigation was carried out on 40 male rats (weight from180 to 220 g) which were assigned to four groups (10/each): (the first) a negative control group (not receiving therapy), (the second) a positive control group (diabetic group) injected with alloxan only (160 mg/kg), (the third) diabetic group administered with Vildagliptin (6mg/kg) and the forth diabetic group treated with Bee venom (0.5mg/kg). After two months of the investigation, blood samples were assembled.
Results:
Bee Venom (0.5mg/kg) lowered significantly (p≤0.05) the level of serum glucose, which was followed by a substantial rise in the level of HDL and insulin when contrasted to the rats with diabetes. Total lipid, cholesterol, triacylglycerol and LDL levels were considerably reduced in the diabetic group that received BV.
Conclusion:
There is a growing interest in the bee venom's use as a natural product rather than chemical drugs for treatment of diabetes mellitus because of the manner it affects rats biochemically, particularly its prospective anti-diabetic and anti-hyperlipidemia qualities.
Key words: Bee venom; Alloxan; Vildagliptin; Diabetes type 2; oxidative stress, biochemical indices (insulin; lipid profile).
|
